Exosome Diagnostics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 98

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $15M

Exosome Diagnostics General Information

Description

Developer of biofluid-based diagnostics designed to deliver personalized precision healthcare that improves lives. The company's biofluid-based diagnostics harness the power of exosomes, important cell messengers carried within biofluids, such as serum, plasma, urine, cerebrospinal fluid and saliva, that contain RNA, DNA and proteins from their cell of origin, thereby enabling health care organizations or doctors non-invasive diagnosis of serious diseases, aiming to reduce or eliminate the need for tissue biopsies.

Contact Information

Formerly Known As
Exosome Theranostics, Exosome Theranostics, Inc.
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 266 Second Avenue
  • Suite 200
  • Waltham, MA 02451
  • United States
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 266 Second Avenue
  • Suite 200
  • Waltham, MA 02451
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exosome Diagnostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 15-Sep-2025 $15M Completed Generating Revenue
6. Merger/Acquisition 01-Aug-2018 Completed Generating Revenue
5. Later Stage VC (Series C) 05-Jul-2017 Completed Generating Revenue
4. Later Stage VC (Series B2) 07-Jan-2016 Completed Generating Revenue
3. Later Stage VC (Series B) 12-Mar-2014 Completed Generating Revenue
2. Grant 01-Feb-2012 $1.29M $20M Completed Startup
1. Early Stage VC (Series A) 11-May-2010 $20M $20M Completed Startup
To view Exosome Diagnostics’s complete valuation and funding history, request access »

Exosome Diagnostics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B2
Series B 1,843,597 $0.010000 $1.07 $14.24 $14.24 1x $14.24 14.92%
Series A 629,162 $0.010000 $1.11 $13.82 $13.82 1x $13.82 5.09%
To view Exosome Diagnostics’s complete cap table history, request access »

Exosome Diagnostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biofluid-based diagnostics designed to deliver personalized precision healthcare that improves lives. The c
Laboratory Services (Healthcare)
Waltham, MA
98 As of 2025

Fremont, CA
 

Vancouver, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exosome Diagnostics Competitors (31)

One of Exosome Diagnostics’s 31 competitors is BioGenex Laboratories, a Corporation company based in Fremont, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioGenex Laboratories Corporation Fremont, CA
Boreal Genomics Formerly VC-backed Vancouver, Canada
CirculoGene Venture Capital-Backed Birmingham, AL
Foundation Medicine Formerly VC-backed Boston, MA
Decipher Urologic Cancers Formerly VC-backed San Diego, CA
You’re viewing 5 of 31 competitors. Get the full list »

Exosome Diagnostics Patents

Exosome Diagnostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4584397-A1 Methods of detecting sjögren's syndrome using salivary exosomes Pending 07-Sep-2022
WO-2024054572-A1 Methods of detecting sjögren's syndrome using salivary exosomes Inactive 07-Sep-2022
WO-2023158869-A1 Use of microvesicle signatures in the identification and treatment of renal disorders Inactive 18-Feb-2022
EP-4370712-A1 Methods of detecting sjögren's syndrome using salivary exosomes Pending 16-Jul-2021
WO-2023288130-A1 Methods of detecting sjögren's syndrome using salivary exosomes Inactive 16-Jul-2021 C12Q1/6832
To view Exosome Diagnostics’s complete patent history, request access »

Exosome Diagnostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exosome Diagnostics Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arcus Ventures Venture Capital Minority
Bio-Techne Corporation Majority
Blue Ridge Capital Real Estate Minority
CD-Venture Venture Capital Minority
Forbion Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Exosome Diagnostics FAQs

  • When was Exosome Diagnostics founded?

    Exosome Diagnostics was founded in 2008.

  • Where is Exosome Diagnostics headquartered?

    Exosome Diagnostics is headquartered in Waltham, MA.

  • What is the size of Exosome Diagnostics?

    Exosome Diagnostics has 98 total employees.

  • What industry is Exosome Diagnostics in?

    Exosome Diagnostics’s primary industry is Laboratory Services (Healthcare).

  • Is Exosome Diagnostics a private or public company?

    Exosome Diagnostics is a Private company.

  • What is the current valuation of Exosome Diagnostics?

    The current valuation of Exosome Diagnostics is .

  • What is Exosome Diagnostics’s current revenue?

    The current revenue for Exosome Diagnostics is .

  • How much funding has Exosome Diagnostics raised over time?

    Exosome Diagnostics has raised $137M.

  • Who are Exosome Diagnostics’s investors?

    Arcus Ventures, Bio-Techne, Blue Ridge Capital, CD-Venture, and Forbion are 5 of 11 investors who have invested in Exosome Diagnostics.

  • Who are Exosome Diagnostics’s competitors?

    BioGenex Laboratories, Boreal Genomics, CirculoGene, Foundation Medicine, and Decipher Urologic Cancers are some of the 31 competitors of Exosome Diagnostics.

  • When was Exosome Diagnostics acquired?

    Exosome Diagnostics was acquired on 15-Sep-2025.

  • Who acquired Exosome Diagnostics?

    Exosome Diagnostics was acquired by MDxHealth.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process